ClinicalTrials.gov record
Terminated No phase listed Observational Results available

Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis

ClinicalTrials.gov ID: NCT00688545

Public ClinicalTrials.gov record NCT00688545. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 1:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

SINCERE™: Safety in Idiopathic Arthritis: NSAIDs and Celebrex Evaluation Registry A Prospective Observational Registry Of Patients With Juvenile Idiopathic Arthritis (JIA) Treated With NSAIDs

Study identification

NCT ID
NCT00688545
Recruitment status
Terminated
Study type
Observational
Phase
Not listed
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Enrollment
275 participants

Conditions and interventions

Interventions

  • Celecoxib Drug
  • nsNSAIDs Drug

Drug

Eligibility (public fields only)

Age range
2 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2009
Primary completion
Dec 31, 2011
Completion
Dec 31, 2011
Last update posted
Feb 1, 2021

2009 – 2012

United States locations

U.S. sites
27
U.S. states
13
U.S. cities
26
Facility City State ZIP Site status
Pfizer Investigational Site Phoenix Arizona 85006
Pfizer Investigational Site Little Rock Arkansas 72202
Pfizer Investigational Site Washington D.C. District of Columbia 20010
Pfizer Investigational Site Arlington Heights Illinois 60005
Pfizer Investigational Site Chicago Illinois 60637
Pfizer Investigational Site Glenview Illinois 60025
Pfizer Investigational Site New Lenox Illinois 60451
Pfizer Investigational Site Westchester Illinois 60154
Pfizer Investigational Site Omaha Nebraska 68114
Pfizer Investigational Site Hackensack New Jersey 07601
Pfizer Investigational Site Livingston New Jersey 07039
Pfizer Investigational Site Brooklyn New York 11211
Pfizer Investigational Site Brooklyn New York 11214
Pfizer Investigational Site Commack New York 11725
Pfizer Investigational Site Great Neck New York 11021
Pfizer Investigational Site New Hyde Park New York 11040
Pfizer Investigational Site New York New York 10016
Pfizer Investigational Site Durham North Carolina 27710
Pfizer Investigational Site Cincinnati Ohio 45229-3026
Pfizer Investigational Site Cleveland Ohio 44106
Pfizer Investigational Site Liberty Township Ohio 45044
Pfizer Investigational Site Mayfield Heights Ohio 44124
Pfizer Investigational Site Strongsville Ohio 44136
Pfizer Investigational Site Philadelphia Pennsylvania 19134-1095
Pfizer Investigational Site Charleston South Carolina 29425
Pfizer Investigational Site Nashville Tennessee 37232-9263
Pfizer Investigational Site Austin Texas 78723

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00688545, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 1, 2021 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00688545 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →